It's nice to see that Kyowa is committed to conducting Kyowa-specific studies and adhering to FDA GRAS regulations
Activacin del receptor LRP1 : hiptesis emergente de receptor primario en queratinocitos y fibroblastos
In rodent tendon and ligament injury models, treated animals showed accelerated tenocyte proliferation and faster collagen-fiber organization versus controls
This does not mean that melanotan, used on a short-term basis to achieve desired benefits will cause CMM, but only that the concern is based on a solid rationale
Example, if you want to administer 100mcg of IGF-1 Lr3 into the chest in 2 different areas of the muscle then you would need to divided the dose as follows: 100mcg per administration / 2 chest muscles = 50mcg per muscle 50mcg per muscle / 2 different locations on each muscle = 25mcg per injection Theoretically, the more locations used to administer the IGF-1 Lr3 into the muscle the more places for muscle growth
MCP, monocyte chemoattractant